Neurology

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.

The approval is a milestone for rare disease that has lacked treatments capable of crossing the blood-brain barrier and introduces a new class of agent that pharmacists will need to understand.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

The authors urge air quality interventions to promote and support dementia prevention strategies.

Neurology CPAs let pharmacists speed multiple sclerosis therapy, order labs and meds, cut delays, boost adherence, and expand collaborative care.

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

The most pronounced association was observed when individuals consumed 2 to 3 cups of caffeinated coffee per day.

Although historically conceptualized as a childhood condition, it is now well established that ADHD frequently continues across the life span, with symptoms evolving rather than resolving.

The HHS secretary overstated preliminary research showing the benefits of a keto diet in patients with schizophrenia who remain adherent to medications.

Embedded pharmacy experts in neurology strengthen multiple sclerosis care through education, therapy selection, lab monitoring, and collaborative practice agreements that close gaps.

In addition to increased prevalence, the age of diagnosis has also decreased.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.

Pharmacists should know about migraine treatments, such as lasmiditan, to effectively treat and educate patients with acute migraine.

The authors suggested that future research investigate emerging blood-based biomarkers and explore temporal associations between sleep duration and Alzheimer disease biomarker changes.

Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.

The FDA prioritizes centanafadine's review for ADHD treatment, offering a novel, once-daily oral option for diverse patient needs.